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HONEST Study: Morning Home Blood Pressure (BP) 
May be Superior to Clinic BP as a Predictor of Coronary 
Events and Stroke in Patients With Hypertension 
In 21,591 hypertensive patients (mean age ~65 years), 
having 127 stroke and 121 CAD events over a mean follow-
up of 2 years, the incidence of stroke events was significantly 
higher in patients with morning home systolic blood pressure 
(HSBP) ≥145 mmHg compared with <125 mmHg (hazard ratio 
- HR ~6.0), and in patients with clinic systolic blood pressure 
(CSBP) ≥150 mmHg compared with <130 mmHg (HR 5.82); 
morning HSBP predicted stroke events similarly to CSBP. 
Incidence of CAD events was significantly higher in patients 
with morning HSBP ≥145 mmHg compared with <125 mmHg 
(HR 6.24) and in patients with CSBP ≥160 mmHg compared 
with <130 mmHg (HR 3.51). Thus, compared with morning 
HSBP predicted CAD events more strongly than CSBP (Kario 
K et al, J Am Coll Cardiol 2016;67:1519-1527).
A 1-h Combination Algorithm Allows Fast Rule-Out 
/ Rule-In of Major Adverse Cardiac Events (MACE): 
In Patients with Chest Pain Presenting to Emergency 
Department (ED), Combining hs-cTnT Levels on 
Arrival and 1 h Later With the Patient History and 
ECG More Effectively Identified MACE Within 30 
Days Than Screening Based on hs-cTnT Alone
In a prospective observational study enrolling 1,038 pa-
tients presenting to the emergency department (ED) with chest 
pain, an extended algorithm comprising hs-cTnT results at 1 h 
combined with history and ECG, identified 60% of all patients 
for rule-out and had a higher sensitivity than the troponin 
algorithm alone (97.5% vs 87.6%; p <0.001). The negative 
predictive value was 99.5% and the likelihood ratio was 0.04 
with the extended algorithm vs 97.8% and 0.17, respectively, 
with the troponin algorithm. The extended algorithm ruled-in 
14% of patients with a higher sensitivity (75.2% vs 56.2%; 
p <0.001) but a slightly lower specificity (94.0% vs 96.4%; 
p <0.001) than the troponin algorithm. The rule-in arms of 
both algorithms had a likelihood ratio >10 (Mokhtari A et al, 
J Am Coll Cardiol 2016;67:1531-1540).
CTSN Trial: Strategies for Rate and Rhythm Control 
to Treat Postoperative Atrial Fibrillation (AF): 
Neither Treatment Strategy Showed a Net Clinical 
Advantage Over the Other / They were Associated With 
Equal Numbers of Days of Hospitalization, Similar 
Complication Rates, and Similarly Low Rates of 
Persistent AF 60 Days After Onset 
Among 695 of 2109 patients (33%) who had AF after 
cardiac surgery, 523 underwent randomization to heart-rate 
or rhythm control. The total numbers of hospital days were 
similar in the 2 groups (median, 5.1 and 5 days, respectively; 
P=NS). There were no significant between-group differences 
in the rates of death (P=NS) or overall serious adverse events 
(24.8 per 100 patient-months in the rate-control group and 26.4 
per 100 patient-months in the rhythm-control group, P=NS), 
including thromboembolic and bleeding events. About 25% 
of patients in each group deviated from the assigned therapy, 
mainly because of drug ineffectiveness (in the rate-control 
group) or amiodarone side effects or adverse drug reactions (in 
the rhythm-control group). At 60 days, 93.8% of the patients in 
the rate-control group and 97.9% of those in the rhythm-control 
group had had a stable heart rhythm without AF for the previ-
ous 30 days (P=0.02), and 84.2% and 86.9%, respectively, had 
been free from AF from discharge to 60 days (P=NS) (Gillinov 
AM et al, N Engl J Med 2016; 374:1911-1921). 
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COGENT: Gastroprotection With Proton Pump 
Inhibitors (PPIs) Should be Utilized in Appropriately 
Selected Patients With Coronary Artery Disease 
Requiring Dual Antiplatelet Therapy (DAPT), Even if 
Patients are on Low-Dose Aspirin
High-dose aspirin users (n=1,272 or 34%; higher rates 
of hyperlipidemia, smoking and history of PCI) had similar 
6-month Kaplan-Meier estimates of adjudicated composite 
gastrointestinal (GI) events (1.7% vs 2.1%; hazard ratio - HR: 
0.88) and major adverse cardiac events (4.8% vs 5.5%; HR: 
0.73) compared with low-dose aspirin users (n=2,480 or 66%; 
older, female, and with higher rates of peripheral artery disease, 
prior stroke, and hypertension). Randomization to PPI therapy 
reduced 6-month Kaplan-Meier estimates of the primary GI 
endpoint in low-dose (1.2% vs 3.1%) and high-dose aspirin 
subsets (0.9% vs 2.6%), and did not adversely affect the pri-
mary cardiovascular endpoint in either group (Vaduganathan 
M et al, J Am Coll Cardiol 2016;67:1661-1671).
Left Ventricular Assist Device (VAD) May Improve 
Clinical Outcomes of Patients With Acute Myocardial 
Infarction (AMI) and Heart Failure Who do not 
Respond Adequately to Conventional Therapy
VAD were implanted in 502 patients with AMI and 66% were 
INTERMACS profile 1 in 66% (median age 58.3 years, 77% 
male): 443 left VADs; 33 bi-VADs; and 26 total artificial hearts. 
A higher proportion of AMI than non-AMI patients had pre-
operative intra-aortic balloon pumps (57.6% vs 25.3%; p <0.01), 
intubation (58% vs 8.3%; p <0.01), extracorporeal membrane 
oxygenation (17.9% vs 1.7%, p <0.01), cardiac arrest (33.5% 
vs 3.3%, p <0.01), and higher-acuity INTERMACS profiles. 
At 1 month post-VAD, 91.8% of AMI patients were alive with 
ongoing device support, 7.2% had died on device, and 1% had 
been transplanted. At 1-year post-VAD, 52% of AMI patients 
were alive with ongoing device support, 25.7% had been trans-
planted, 1.6% had left VAD explanted for recovery, and 20.7% 
had died on device. The AMI group had higher early phase hazard 
(hazard ratio - HR: 1.24; p=0.04) and reduced late-phase hazard 
of death (HR: 0.57; p=0.04) than the non-AMI group did. After 
accounting for established risk factors, the AMI group no longer 
had higher early mortality hazard (HR: 0.89; p=0.30), but it had 
lower late mortality hazard (HR: 0.55; p=0.02) (Acharya D et 
al, J Am Coll Cardiol 2016;67:1871-1880).
ALBATROSS Trial: A Mineralocorticoid Receptor 
Antagonist (MRA) Given Early After Myocardial 
Infarction (MI) did not Reduce the Composite of 
Death, Ventricular Arrhythmia, Cardiac Arrest, Need 
for Implantable Defibrillator, or New or Worsening 
Heart Failure (HF) at 6 Months, but Seemed to Lower 
Mortality Among Those Presenting With ST-Segment 
Elevation MI (STEMI)
Among 1,603 patients presenting with acute MI (92% of 
whom presented without HF) and randomized to receive an 
MRA regimen with a single intravenous bolus of potassium 
canrenoate (200 mg) followed by oral spironolactone (25 mg 
once daily) for 6 months in addition to standard therapy or 
standard therapy alone, the primary outcome occurred in 95 
(11.8%) and 98 (12.2%) patients in the treatment and control 
groups, respectively (hazard ratio - HR: 0.97). Death occurred 
in 11 (1.4%) and 17 (2.1%) patients in the treatment and con-
trol groups, respectively (HR: 0.65). The odds of death were 
reduced in the treatment group (3 or 0.5% vs 15 or 2.4%; 
HR: 0.20) in the subgroup of STEMI (n=1,229), but not in 
non–STEMI (p for interaction = 0.01). Hyperkalemia >5.5 
mmol/l–1 occurred in 3% and 0.2% of patients in the treatment 
and standard therapy groups, respectively (p < 0.0001) (Beygui 
F et al, J Am Coll Cardiol 2016;67:1917-1927).
Takotsubo (TS) Registry: Patients Predisposed To 
TS Stress Cardiomyopathy Typically Have a Low 
Cardiovascular Risk Profile But Increased COPD, 
Migraine and Affective Disorders. Risk is Increased 
in Those Using Β2-Adrenergic Agonist Agents and 
Medications for Migraine / Mortality Rate is Similar to 
Patients With Acute Coronary Syndromes 
Of the 505 patients with TS cardiomyopathy (TSC), 442 
(87.5%) were women (mean age of 67±10 years). The largest 
age group was between 60 and 69 years old with one-fifth of 
the patients <60 years of age. Compared with CAD control 
subjects (n=1,010), patients with TSC were characterized by 
a low cardiovascular risk factor profile but with increased 
chronic obstructive pulmonary disease (COPD), migraine, and 
affective disorders. The use of beta-blockers was less common 
but use of β2-adrenergic agonist agents was more common in 
patients with TSC compared with either of the control groups. 
Being a patient with TSC was associated with a hazard ratio 
of 2.1 for death compared with the control subjects without 
CAD (n=1,007). This was similar to the excess mortality risk 
seen among the CAD control subjects compared with control 
subjects without CAD (hazard ratio: 2.5) (Tornvall P et al, J 
Am Coll Cardiol 2016;67:1931-1936).
UK Registry: Causes of Sudden Cardiac Death (SCD) 
in Athletes Vary With Age / Sudden Arrhythmic 
Death Syndrome (SADS) is Prevalent in Children and 
Adolescents, Whereas Cardiomyopathies are the Most 
Common Cause in Adults / Arrhythmogenic Right 
Ventricular Cardiomyopathy (ARVC) is Strongly 
Associated With SCD During Exertion
Autopsies were performed in 357 consecutive cases of 
athletes who died suddenly (mean 29±11 years of age, 92% 
males, 76% Caucasian, 69% competitive). Sudden arrhythmic 
death syndrome (SADS) was the most prevalent cause of 
death (n=149 or 42%), mostly in young athletes. This was a 
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diagnosis of exclusion, defined as a structurally normal heart 
with no evident abnormality on macroscopic and histologi-
cal evaluation and a negative result for toxicology screening, 
underscoring the importance of inherited primary arrhythmia 
syndromes as a major cause of SCD in athletes. Myocardial 
disease was detected in 40% of cases (mostly older athletes), 
including idiopathic left ventricular hypertrophy (LVH) and/
or fibrosis (n=59, 16%); ARVC (13%); and hypertrophic 
cardiomyopathy (HCM) (6%). Coronary artery anomalies 
occurred in 5% of (mostly young) cases. SCD during intense 
exertion occurred in 61% of cases (particularly in ARVC and 
left ventricular fibrosis). Almost 40% of athletes die at rest, 
highlighting the need for complementary preventive strategies 
(Finocchiaro G et al, J Am Coll Cardiol 2016;67:2108-2115).
BLOCK HF Trial: In Patients With AV Block (AVB) 
& Heart Failure, Biventricular Compared With RV 
Pacing is Associated With Improvement in Survival, 
Heart Failure-Related Urgent Care, and Adverse 
Ventricular Remodeling, Better Functional Capacity 
and Quality of Life 
Among 691 patients with AVB, NYHA symptom class I 
to III heart failure, and left ventricular ejection fraction ≤50% 
randomized to biventricular (n=349) or right ventricular 
(RV) pacing (n=342), biventricular pacing conferred greater 
improvement in NYHA class at 12 months, with 19% im-
proved, 61% unchanged, and 17% worsened, compared with 
12%/62%/23% in the RV arm. QOL was improved through 12 
months. At 6 months, clinical composite score was improved/
unchanged/ worsened in 53%/24%/24% in the biventricular 
arm compared with 39%/33%/28% in the RV arm. This im-
provement was sustained through 24 months (Curtis AB et al, 
J Am Coll Cardiol 2016;67:2148-2157).
OBSERVANT Study: In Patients With Low Operative 
Risk, Significantly Better 3-Year Survival and Freedom 
From Major Adverse Cardiac and Cerebrovascular 
Events (MACCE) were Observed after Surgical 
Aortic Valve Replacement (SAVR) Compared With 
Transcatheter Aortic Valve Implantation (TAVI) 
One month survival was 97.1% after SAVR and 97.4% 
after TAVI (P=NS) among 355 low-risk patients in each 
group (EuroSCORE II <4%). Cardiac tamponade, pacemaker 
implantation, major vascular damage, and moderate-to-severe 
paravalvular regurgitation were significantly more frequent 
after TAVI compared with SAVR. Stroke rates were equal. 
SAVR was associated with higher risk of cardiogenic shock, 
severe bleeding, and acute kidney injury. At 3 years, survival 
was 83.4% after SAVR and 72% after TAVI (P=0.0015), and 
freedom from MACCE was 80.9% after SAVR and 67.3% 
after TAVI (P <0.001) (Rosato S et al, Circ Cardiovasc Interv 
2016;9:e003326).
PARTNER II: In Intermediate-Risk Patients, TAVI was 
Similar to Surgical Aortic-Valve Replacement (AVR) 
With Respect to Death or Disabling Stroke
Among 2032 intermediate-risk (STS risk score of ≥4% and 
<8%) patients with severe aortic stenosis, randomly assigned 
to TAVI or surgical AVR, the rate of death from any cause or 
disabling stroke was similar (P=0.001 for noninferiority). At 2 
years, the Kaplan–Meier event rates were 19.3% in the TAVI 
and 21.1% in the surgery group (hazard ratio – HR in TAVI, 
0.89; P=NS). In the trans-femoral-access cohort, TAVI resulted 
in a lower rate of death or disabling stroke than surgery (HR, 
0.79; P=0.05), whereas in the transthoracic-access cohort, 
outcomes were similar in the two groups. TAVI resulted in 
larger aortic-valve areas and also in lower rates of acute kid-
ney injury, severe bleeding, and new-onset atrial fibrillation; 
surgery resulted in fewer major vascular complications and 
less paravalvular aortic regurgitation (Leon MB et al, N Engl 
J Med 2016; 374:1609-1620).
Propensity Score Analysis: TAVI With SAPIEN 3 in 
Intermediate-Risk Severe Aortic Stenosis Patients 
Confers Low Mortality, Strokes, & Regurgitation at  
1 Year & Appears Superior to Surgery
At 1 year follow-up of the SAPIEN 3 observational study, 
79 of 1077 intermediate-risk patients had died (all-cause 
mortality 7.4%; 6.5% in the transfemoral access subgroup), 
and disabling strokes had occurred in 24 (2%), aortic valve 
re-intervention in 6 (1%), and moderate or severe paravalvu-
lar regurgitation in 13 (2%). In the propensity-score analysis 
comprising 963 TAVI patients receiving SAPIEN 3 and 747 
with surgical valve replacement (PARTNER 2A trial), for the 
primary composite endpoint of mortality, strokes, and moder-
ate or severe aortic regurgitation, TAVI was both non-inferior 
(pooled weighted proportion difference of -9.2%; p <0.0001) 
and superior (-9.2%; p <0.0001) to surgical valve replacement 
(Thourani VH et al, Lancet 2016; 387 (10034):2218–2225). 
A Case–Control Study: Deficiency of the Aortic or any 
Rim, Device >5 mm Larger than ASD Diameter, and 
Weight: Device Size Ratio are Risk Factors for Cardiac 
Erosion Following Transcatheter Closure of Atrial 
Septal Defects (ASDs)
Among 125 erosions reported after ASD closure with an 
Amplatzer septal occlude, the median duration from implant 
to erosion was 14 days, but was >1 year in 16 patients. Nine 
patients (aged ≥17 years) who died were more likely to have 
an oversized device, and to have erosion into the aorta, than 
survivors. Aortic or superior vena cava rim deficiencies were 
more common in cases than in controls. In addition, larger 
balloon-sized ASD diameter, Amplatzer septal occluder device 
size, and device size–ASD diameter difference, and smaller 
weight-to-device size ratio were associated with erosion. On 
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multivariable analysis, deficiency of any rim, device >5 mm 
larger than ASD diameter, and weight:device size ratio were 
associated with erosion (McElhinney DB et al, Circulation 
2016; 133:1738-1746. 
The ABC (Age, Biomarkers, Clinical History) Stroke 
Risk Score: A Better Biomarker-Based Risk Score for 
Predicting Stroke in Atrial Fibrillation?
A new risk score, the ABC (Age, Biomarkers, Clinical 
history) score, was developed and validated in 14,701 AF 
patients, with further external validation in another 1400 AF 
patients. The most important predictors were prior stroke/
transient ischemic attack, NT-proBNP, cTn-hs, and age. The 
ABC-stroke score was well calibrated and yielded higher c-
indices than the widely used CHA2DS2-VASc score in both the 
derivation cohort (0.68 vs. 0.62, P <0.001) and the external 
validation cohort (0.66 vs. 0.58, P <0.001) (Hijazi Z et al, Eur 
Heart J 2016; 37:1582-1590).
ARISTOTLE /RE-LY Investigators: ABC-Bleeding 
Score, Using Age, Bleeding History, & 3 Biomarkers 
(Hemoglobin, cTn-hs, and GDF-15 or Cystatin C/CKD-
EPI) Performed Better than HAS-BLED & ORBIT 
Scores in Patients with Atrial Fibrillation (AF)
The ABC-bleeding score (age, biomarkers [growth dif-
ferentiation factor-15 or GDF-15, high-sensitivity cardiac 
troponin T or cTnT-hs, and hemoglobin], and clinical history of 
previous bleeding) yielded a higher c-index than HAS-BLED 
and ORBIT scores for major bleeding in both the derivation 
(n=14,537, ARISTOTLE trial) cohort (0.68 vs 0.61 vs 0.65, 
respectively; ABC-bleeding vs HAS-BLED p <0.0001 and 
ABC-bleeding vs ORBIT p=0.0008), and in the external 
validation (n=8468, RE-LY trial) cohort (0.71 vs 0.62 for 
HAS-BLED vs 0.68 for ORBIT; ABC-bleeding vs HAS-
BLED p <0.0001 and ABC-bleeding vs ORBIT p=0.0016). 
A modified ABC-bleeding score using alternative biomarkers 
(hematocrit, cTnI-hs, cystatin C, or creatinine clearance) also 
outperformed the HAS-BLED and ORBIT scores (Hijazi Z et 
al, Lancet 2016; 387 (10035): 2302–2311). 
ACC PINNACLE Registry: High Undertreatment 
Rate (38-40%) With Aspirin Alone Instead of Oral 
Anticoagulant (OAC) in Atrial Fibrillation Patients at 
Risk for Stroke, Usually Associated With Conditions 
Related to Coronary Disease (CAD)
Among 210,380 AF patients with CHADS2 score ≥2, 
80,371 (38.2%) were treated with aspirin alone, and 130,009 
(61.8%) with warfarin or non-vitamin K antagonist OACs. In 
another cohort of 294,642 patients with CHA2DS2-VASc ≥2, 
118,398 (40.2%) were treated with aspirin alone, and 176,244 
(59.8%) with warfarin or non-vitamin K antagonist OACs. 
After multivariable adjustment, hypertension, dyslipidemia, 
CAD, prior MI, unstable and stable angina, recent CABG, and 
peripheral arterial disease were associated with prescription of 
aspirin only, whereas male gender, higher body mass index, 
prior stroke/TIA, prior systemic embolism, and congestive 
heart failure were associated with more frequent prescription 
of OAC (Hsu J et al; J Am Coll Cardiol 2016; 67:2913-2923). 
Non-Paroxysmal (NPAF) Compared to Paroxysmal 
Atrial Fibrillation (PAF) is Associated With a Highly 
Significant Increase in Thromboembolism and Death
According to 12 studies comprising 99,996 patients, the 
unadjusted risk ratio (RR) for thromboembolism in NPAF vs 
PAF was 1.355 (P <0.001). In the study subset off oral anti-
coagulation, unadjusted RR was 1.689 (P=0.007). The overall 
multivariable adjusted hazard ratio (HR) for thromboembolism 
was 1.384 (P <0.001). The overall unadjusted RR for all-cause 
mortality was 1.462 (P <0.001) and the adjusted HR for all-
cause mortality was 1.217 (P <0.001). Rates of bleeding were 
similar (Ganesan AN et al, Eur Heart J 2016;37:1591-1602). 
VINDICATE Study: In Patients With Chronic Heart 
Failure (HF), Vitamin D Deficiency is Common, and 
High-Dose Vitamin D3 Supplementation is Safe, Well 
Tolerated, and Associated With a Favorable Effect on 
Cardiac Function 
Among 229 patients (179 men) with chronic HF and 
vitamin D deficiency (cholecalciferol <50 nmol/l or <20 ng/
ml), randomized to 1 year of vitamin D3 (4,000 IU or 100 μg 
daily) or matching non−calcium-based placebo, the 6-min 
walk distance at 1 year did not improve, but there was a sig-
nificant improvement in cardiac function (ejection fraction 
+6.07%; p <0.0001); and a reversal of LV remodeling (LV 
end diastolic diameter -2.49 mm and LV end systolic diam-
eter -2.09 mm (p= 0.043) (Witte KK et al, J Am Coll Cardiol 
2016;67:2593-2603.).
Percutaneous Mitral Valve Plication With the Mitral 
Clip May be Effective for Symptom Relief in Patients 
With Obstructive Hypertrophic Cardiomyopathy 
(HCM) via Reduction of Systolic Anterior Motion 
(SAM) and Mitral Regurgitation (MR) 
Percutaneous mitral valve leaflet plication to reduce SAM 
and MR using the transcatheter mitral clip system was com-
pleted in 5 of 6 referred patients (age 83±8 years; 5 women) 
(one patient had cardiac tamponade and the procedure was 
aborted). SAM was eliminated and the intraoperative LVOT 
gradient (91±44 mmHg to 12±6 mmHg; p= 0.007), left atrial 
pressure (29±11 mmHg to 20±8 mmHg; p= 0.06), and MR 
grade (3.0±0 vs. 0.8±0.4; p=0.0002) were decreased, associ-
ated with improved cardiac output (in n=4; 3.0±0.6 l/min to 
4.3±1.2 l/min; p=0.03). Over 15±4 months, symptom improve-
ment to NYHA class I or II occurred in all patients. Follow-up 
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echocardiography demonstrated continued absence of SAM 
and significant reduction in MR, although high systolic LVOT 
velocities (i.e., >4 m/s) were evident in 3 of the 5 treated pa-
tients (Sorajja P et al, J Am Coll Cardiol 2016;67:2811-2818). 
EARLY-BAMI Trial: In Patients With Acute STEMI 
Given IV Metoprolol within 12 h Before Primary 
Angioplasty, Infarct Size Measured by CMR was not 
Significantly Different Than in Those Given a Placebo
A total of 683 STEMI patients (mean age 62±12 years; 
75% male) presenting within 12 h were randomized to IV 
metoprolol (n=336) or placebo (n=346). Infarct size by cardiac 
magnetic resonance (CMR) (performed in 342 patients) did not 
differ between the metoprolol (15.3±11%) and placebo groups 
(14.9±11.5%; p=0.616). Peak and area under the creatine kinase 
curve did not differ between groups. LV ejection fraction by 
CMR did not differ. Incidence of malignant arrhythmias was 
3.6% in the metoprolol group vs 6.9% in placebo (p=0.050). 
Incidence of adverse events was not different between groups 
(Roolvink V et al, J Am Coll Cardiol 2016; 67:2705-2715).
Trimethylamine N-oxide (TMAO), an Intestinal 
Microbe-Generated Phosphatidylcholine Metabolite is 
Related to the Pathogenesis of Atherosclerotic CAD 
TMAO arises from gut microbiota metabolism following 
ingestion of diets rich in phosphatidylcholine (or lecithin), the 
major dietary source of choline, and carnitine, an abundant 
nutrient in red meat. In 353 consecutive stable patients with 
angiographic evidence of CAD, the median TMAO level 
was 5.5 μM, the median SYNTAX score was 11, and 289 
(81.9%), 40 (11.3%), and 24 (6.8%) patients had low (0 to 
22), intermediate (23 to 32), and high (≥33) SYNTAX scores, 
respectively. Plasma TMAO levels correlated (all p <0.0001) 
with the SYNTAX score (r=0.61), SYNTAX score II (r=0.62), 
and hs-cTnT (r=0.29). After adjustment, elevated TMAO levels 
remained independently associated with a higher SYNTAX 
score (odds ratio - OR: 4.82; p <0.0001), SYNTAX score II 
(OR: 1.88; p=0.0001), but were not associated with subclinical 
myonecrosis (OR: 1.14; p=0.3147). Elevated TMAO level was 
an independent predictor of the presence of diffuse lesions, even 
after adjustments for traditional risk factors and for hs-cTnT 
(OR: 2.05; p=0.0001) (Senthong V et al, J Am Coll Cardiol 
2016;67:2620-2628).
The Stepathlon Cardiovascular Health Study: Light 
Weight, Low-Cost, Noninteractive Pedometers Can 
Promote Modest Improvements in Physical Activity, Sitting, 
and Weight Among Private and Public Sector Employees 
Stepathlon, a low-cost, pedometer-based, workplace physi-
cal activity and wellness program, which utilized an mHealth 
technology-based approach to facilitate large-scale imple-
mentation and program delivery, was conducted annually as 
a 100-day event, aiming to encourage participants to increase 
step counts and physical activity. After Stepathlon completion, 
participants (N=69,219, age 36±9 years, 23.9% female, 92% 
lower-middle income countries) recorded improved step count 
(+3,519 steps/day; p <0.0001), exercise days (+0.89 days; 
p <0.0001), sitting duration (−0.74 h; p <0.0001) and weight 
(−1.45 kg; p <0.0001). Improvements occurred in women and 
men, in all geographic regions, and in both high and lower-
middle income countries, with reproducible annual results. 
Predictors of weight loss included step increase, sitting dura-
tion decrease, and increase in exercise days (all p <0.0001) 
(Ganesan AN et al, J Am Coll Cardiol 2016; 67:2453-2463). 
A Study of 1.5 Million Blood Donors: Non-O Blood Groups 
Explain >30% of Venous Thromboembolic Events 
In Denmark and Sweden (1987-2012), a total of 9170 
venous and 24,653 arterial thromboembolic events occurred 
in 1,112,072 blood donors; compared with blood group O, 
non-O blood groups were associated with higher incidence 
of both venous and arterial events. The highest rate ratios 
(RR) were observed for pregnancy-related venous thrombo-
embolism (RR, 2.22), deep vein thrombosis (RR, 1.92), and 
pulmonary embolism (RR, 1.80) (Vasan SK et al, Circulation 
2016;133:1449-1457).
CMR Study in Male Elite Master Athletes: The 
Hypothesis of an Exercise-Induced Arrhythmogenic 
Right Ventricular (RV) Cardiomyopathy is Questioned
Among 33 healthy white competitive elite male master 
endurance athletes (age 30–60 years) with a training history 
of 29±8 years, and 33 pair-matched white controls, undergoing 
cardiopulmonary exercise testing, Doppler and speckle track-
ing echocardiography, and cardiovascular magnetic resonance 
(CMR), indexed left ventricular (LV) (96±13 and 62±10 g/
m2; P<0.001), and RV mass (36±7 and 24±5 g/m2; P<0.001) 
and indexed LV (104±13 and 69±18 mL/m2; P<0.001) and RV 
end-diastolic volume (110±22 and 66±16 mL/m2; P<0.001) 
were significantly increased in athletes in comparison with 
control subjects. RV ejection fraction did not differ between 
athletes and controls (52±8 and 54±6%; P=NS). Pathological 
late enhancement was detected in 1 athlete. No correlations 
were found for LV and RV volumes and ejection fraction with 
NT-proBNP, and high-sensitive troponin was negative in all 
subjects (Bohm P et al, Circulation 2016;133:1927-1935). 
STICHES Trial: Coronary Artery Bypass (CABG) 
Improves Survival in Ischemic Cardiomyopathy
Among 1212 coronary artery disease patients with an 
ejection fraction of ≤35%, randomly assigned to CABG plus 
medical therapy (CABG group, n=610) or medical therapy 
alone (medical-therapy group, n=602), over 9.8 years, death 
occurred in 359 patients (58.9%) in the CABG group and in 
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398 patients (66.1%) in the medical group (hazard ratio – HR 
with CABG vs medical therapy, 0.84; P=0.02). A total of 247 
patients (40.5%) in the CABG group and 297 patients (49.3%) 
in the medical-therapy group died from cardiovascular causes 
(HR, 0.79; P=0.006). Death from any cause or hospitalization 
for cardiovascular causes occurred in 467 patients (76.6%) in 
the CABG and in 524 patients (87.0%) in the medical group 
(HR, 0.72; P<0.001) (Velazquez EJ et al, N Engl J Med 2016; 
374:1511-1520). 
Resuscitation Outcomes Consortium (ROC): In Out-
Of-Hospital Cardiac Arrest (OOHCA) Due to Shock-
Refractory VF or Pulseless VT, Neither Amiodarone 
Nor Lidocaine Resulted in a Higher Rate of Survival or 
Favorable Neurologic Outcome Than Placebo 
Among 3026 OOHCA patients, randomly assigned to 
amiodarone (974), lidocaine (993), or placebo (1059), 24.4%, 
23.7%, and 21%, respectively, survived to hospital discharge. 
The difference in survival rate for amiodarone vs placebo was 
3.2% (P=0.08); for lidocaine vs placebo, 2.6%; and for ami-
odarone vs lidocaine, 0.7% (P=0.70). Neurologic outcome at 
discharge was similar in the 3 groups. There was heterogene-
ity of treatment effect with respect to whether the arrest was 
witnessed (P=0.05); both drugs were associated with a higher 
survival rate than placebo among patients with bystander-
witnessed arrest but not among those with unwitnessed arrest. 
More amiodarone recipients required temporary cardiac pacing 
(Kudenchuk PJ et al, N Engl J Med 2016; 374:1711-1722).
HOPE-3 Trials: Among Persons at Intermediate Risk 
With no Cardiovascular Disease, Antihypertensive 
Therapy With Candesartan plus Diuretic Does not 
Protect from Major Cardiovascular Events, but 
Therapy With Rosuvastatin or Combined Rosuvastatin 
and Candesartan plus Hydrochlorothiazide Does
Among 12,705 participants at intermediate risk with 
no cardiovascular disease (mean baseline blood pressure 
138.1/81.9 mmHg) randomly assigned to candesartan (16 
mg/d) plus hydrochlorothiazide (12.5 mg/d) or placebo, over 
a median follow-up of 5.6 years, the decrease in blood pres-
sure was 6/3 mmHg greater in the active-treatment group. The 
first coprimary outcome (composite of cardiovascular death, 
nonfatal MI, or stroke) occurred in 260 participants (4.1%) 
with active-treatment and in 279 (4.4%) with placebo (hazard 
ratio-HR, 0.93; P=NS); the second coprimary outcome (heart 
failure, cardiac arrest, or revascularization) occurred in 312 
participants (4.9%) and 328 participants (5.2%), respectively 
(HR, 0.95; P=NS) (Lonn EM et al, N Engl J Med 2016; 
374:2009-2020). 
In the same cohort, random assignment to rosuvastatin (10 
mg/d) or placebo led to 26.5% lower LDL cholesterol in the 
active treatment group. The first coprimary outcome occurred 
in 235 participants (3.7%) in the rosuvastatin group and in 304 
participants (4.8%) in the placebo group (HR, 0.76; P=0.002). 
The results for the second coprimary outcome were consistent 
with the results for the first (occurring in 277 participants or 
4.4% in the rosuvastatin group and in 363 participants or 5.7% 
in the placebo group; HR, 0.75; P<0.001). In the rosuvastatin 
group, there was no excess of diabetes or cancers, but there 
was an excess of cataract surgery (3.8% vs 3.1%; P=0.02) and 
muscle symptoms (5.8% vs 4.7%; P=0.005) (Yusuf S et al, N 
Engl J Med 2016; 374:2021-2031). 
Finally, among those (n=3180) assigned to combined 
therapy (rosuvastatin and the 2 antihypertensive agents) 
compared with the 3168 assigned to dual placebo, the first 
coprimary outcome occurred in 113 participants (3.6%) in the 
combined-therapy group and in 157 (5%) in the dual-placebo 
group (HR, 0.71; P=0.005). The second coprimary outcome 
occurred in 136 participants (4.3%) and 187 participants 
(5.9%), respectively (HR, 0.72; P=0.003). Muscle weakness 
and dizziness were more common in the combined-therapy 
than in the dual-placebo group, but the overall discontinua-
tion rate was similar in the two groups (Yusuf S et al, N Engl 
J Med 2016; 374:2032-2043). 
FIRE AND ICE: Cryoballoon Ablation Noninferior to 
Radiofrequency Ablation With Respect to Efficacy and 
Safety in Patients With Drug-Refractory Paroxysmal 
Atrial Fibrillation (PAF)
Among 762 PAF patients randomized to cryoballoon 
(n=378) or radiofrequency ablation (n=384), over mean follow-
up of 1.5 years, the primary efficacy end point (first documented 
clinical failure, i.e. recurrence of AF, occurrence of atrial flutter 
or atrial tachycardia, use of antiarrhythmic drugs, or repeat 
ablation following a 90-day period after the index ablation, 
occurred in 138 patients in the cryoballoon group and in 143 
in the radiofrequency group (1-year event rates, 34.6% and 
35.9%, respectively; hazard ratio-HR, 0.96; P <0.001 for non-
inferiority). The primary safety end point (composite of death, 
cerebrovascular events, or serious treatment-related adverse 
events) occurred in 40 patients in the cryoballoon group and 
in 51 patients in the radiofrequency group (1-year event rates, 
10.2% and 12.8%, respectively; HR, 0.78; P=NS) (Kuck K_H 
et al, N Engl J Med 2016; 374:2235-2245). 
HERMES Collaboration Meta-Analysis of 5 Randomized 
Trials: Endovascular Thrombectomy After Large-Vessel 
Ischemic Stroke is of Benefit to Most Patients / Timely 
Treatment should be Provided to These Patients 
In 2015, 5 randomized trials showed efficacy of endovas-
cular thrombectomy over medical care in patients with acute 
ischemic stroke caused by occlusion of proximal anterior 
cerebral arteries. Patient data for 1287 patients (634 assigned 
to endovascular thrombectomy, 653 assigned to control), 
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pooled from these trials (MR CLEAN, ESCAPE, REVASCAT, 
SWIFT PRIME, and EXTEND IA), indicated that endovas-
cular thrombectomy led to significantly reduced disability 
at 90 days compared with control (adjusted common odds 
ratio-cOR 2.49; p<0.0001). The number needed to treat with 
endovascular thrombectomy to reduce disability by at least 
one level on modified Rankin scale-mRS for one patient was 
2.6. Effect sizes favouring endovascular thrombectomy over 
control were present in several strata of special interest, includ-
ing in patients aged ≥80 years (cOR 3.68), those randomized 
>5h after symptom onset (cOR 1.76), and those not eligible 
for intravenous alteplase (2.43). Mortality at 90 days and 
risk of parenchymal hematoma and symptomatic intracranial 
hemorrhage did not differ between populations (Goyal M et 
al, Lancet 2016; 387(10029):1723–1731). 
DANAMI 3-DEFER: No advantage of Deferred Stent 
Implantation vs Standard PCI in Patients With ST-
Segment Elevation Myocardial Infarction (STEMI)
Among 1215 patients with STEMI randomized to primary 
PCI with immediate stent implantation (n=612) or deferred 
stent implantation 48 h after the index procedure if a stabilized 
flow could be obtained in the infarct-related artery (n=603), at 
a median follow-up of 42 months, the primary endpoint (all-
cause mortality, hospital admission for heart failure, recurrent 
infarction, and any unplanned revascularization of the target 
vessel) occurred in 109 (18%) patients who had standard PCI 
and in 105 (17%) patients who had deferred stent implantation 
(hazard ratio 0·99; p=NS). Procedure-related MI, bleeding 
requiring transfusion or surgery, contrast-induced nephropa-
thy, or stroke occurred in 28 (5%) vs 27 (4%) patients, with 
no significant differences between groups (Kelbæk H et al, 
Lancet 2016; 387 (10034):2199–2206). 
ixCELL-DCM: Transendocardial Delivery of Cellular 
Therapy with Ixmyelocel-T in Patients With Reduced-
Ejection Fraction Ischemic Heart Failure Resulted in 
Significant Reduction in Cardiac Events Compared 
With Placebo Leading to Improved Patient Outcomes 
Ixmyelocel-T is an expanded, multicellular therapy pro-
duced from a patient’s own bone marrow by selectively expand-
ing two key types of bone marrow mononuclear cells: CD90+ 
mesenchymal stem cells and CD45+ CD14+ auto-fluorescent+ 
activated macrophages. Randomized catheter-based transen-
docardial injection of ixmyelocel-T cell therapy in 66 patients 
with heart failure and reduced ejection fraction compared with 
placebo (n=60) led to primary efficacy endpoint (all-cause 
death, cardiovascular admission, and unplanned clinic visits 
to treat acute heart failure) being observed in 47 patients: 50 
events in 25 (49%) of 51 patients in the placebo group and 38 
events in 22 (38%) of 58 patients in the ixmyelocel-T group, 
which represents a 37% reduction in cardiac events compared 
with placebo (risk ratio 0.63; p=0.0344). 41 (75%) of 51 
participants in the placebo group had serious adverse events 
vs 31 (53%) of 58 in the ixmyelocel-T group (p=0.02) (Patel 
AN et al, Lancet 2016; 387:2412–2421). 
GAUSS-3: Among Patients With Statin Intolerance Due 
to Muscle-Related Adverse Effects, Use of Evolocumab 
Compared With Ezetimibe Resulted in a Significantly 
Greater Reduction in LDL-Cholesterol Levels After 24 
Weeks 
Of the 491 patients who entered phase A (20 mg atorvastatin 
vs placebo) (age 60.7±10.2 years; 50% women; 34.6% with 
coronary heart disease; entry mean LDL-C level, 212.3±67.9 
mg/dL), muscle symptoms occurred in 209 (42.6%) while 
taking atorvastatin but not while taking placebo. Of these, 
199 entered phase B, along with 19 who proceeded directly to 
phase B (randomization 2:1 to subcutaneous evolocumab 420 
mg monthly or 10 mg daily of oral ezetimibe) due to elevated 
creatine kinase (n=218, with 73 randomized to ezetimibe and 
145 to evolocumab; entry mean LDL-C level, 219.9±72 mg/
dL). For the mean of weeks 22 and 24, LDL-C with ezetimibe 
was 183 mg/dL (mean percent LDL-C change, -16.7%), and 
with evolocumab 103.6 mg/dL (mean percent change, -54.5%) 
(P <0.001). LDL-C level at week 24 with ezetimibe was 181.5 
mg/dL (mean percent change, -16.7%) and with evolocumab 
was 104.1 mg/dL (mean percent change, -52.8%) (P <0.001). 
For the mean of weeks 22 and 24, between-group difference in 
LDL-C was -37.8%. For week 24, between-group difference in 
LDL-C was -36.1%. Muscle symptoms were reported in 28.8% 
of ezetimibe-treated patients and 20.7% of evolocumab-treated 
patients (log-rank P=NS). Active study drug was stopped for 
muscle symptoms in 5 of 73 ezetimibe-treated patients (6.8%) 
and 1 of 145 evolocumab-treated patients (0.7%) (Nissen SE 
et al, JAMA 2016; 315:1580-1590). 
SPRINT Trial for the Subgroup of Hypertensive Patients 
Aged ≥75 Years: Treating to a Systolic BP (SBP) Target 
of <120 mmHg Compared With <140 mmHg Resulted in 
Significantly Lower Rates of Fatal and Nonfatal Major 
Cardiovascular Events and Death From Any Cause
Among 2636 participants (mean age ~80 years; ~38% 
women; 2510 or ~95% providing complete follow-up data) 
randomized to an SBP target of <120 mmHg (intensive treat-
ment group, n=1317) or an SBP target of <140 mmHg (standard 
treatment group, n=1319), at a median follow-up of 3.14 years, 
there was a lower rate of the primary composite outcome 
(nonfatal MI, other acute coronary syndrome, nonfatal stroke, 
nonfatal acute decompensated heart failure, and cardiovascular 
death) (102 vs 148 events; hazard ratio - HR, 0.66) and all-cause 
mortality (73 deaths vs 107 deaths, respectively; HR, 0.67). 
The overall rate of serious adverse events was not different 
between treatment groups (48.4% vs 48.3%). Absolute rates 
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of hypotension were 2.4% in the intensive treatment group 
vs 1.4% in the standard treatment group (HR, 1.71), 3% vs 
2.4% for syncope (HR, 1.23), 4% vs 2.7% for electrolyte ab-
normalities (HR, 1.51), 5.5% vs 4.0% for acute kidney injury 
(HR, 1.41), and 4.9% vs 5.5% for injurious falls (HR, 0.91) 
(Williamson JD et al, JAMA 2016;315:2673-2682).
Quitting Smoking Abruptly vs Gradually is More 
Likely to Lead to Lasting Abstinence, Even for Those 
Who Initially Prefer to Quit by Gradual Reduction
Among 697 adult smokers with tobacco addiction, all 
receiving behavioral support from nurses and nicotine re-
placement before and after quit day, at 4 weeks, 39.2% of the 
participants in the gradual-cessation group (reduced smok-
ing gradually by 75% in the 2 weeks before quitting) were 
abstinent compared with 49% in the abrupt-cessation group 
(relative risk, 0.80). At 6 months, 15.5% of the participants in 
the gradual-cessation group were abstinent compared with 22% 
in the abrupt-cessation group (relative risk, 0.71). Participants 
who preferred gradual cessation were significantly less likely 
to be abstinent at 4 weeks than those who preferred abrupt 
cessation (38.3% vs 52.2%; P=0.007) (Lindson-Hawley N et 
al, Ann Intern Med 2016;164:585-592).
Systematic Review and Meta-Analysis: Compared 
With Everolimus-Eluting Metallic Stents (EESs), 
Everolimus-Eluting Bioresorbable Vascular Scaffold 
(BVSs) do not Eliminate and Might Increase Risks for 
Stent Thrombosis and MI in Adults Having PCI 
According to 6 randomized, controlled trials and 38 ob-
servational studies, each involving at least 40 patients with 
BVS implantation, the pooled incidence of definite or prob-
able stent thrombosis after BVS implantation was 1.5 events 
per 100 patient-years (PYs) (126 events during 8508 PYs). 
In 6 randomized trials directly comparing BVSs with EESs, a 
non–statistically significant increased risk for stent thrombosis 
(odds ratio - OR, 2.05; P=0.067) and myocardial infarction 
(MI) (OR, 1.38; P=0.064) was observed with BVSs. The 6 
observational studies that compared BVSs with EESs showed 
increased risk for stent thrombosis (OR, 2.32; P=0.035) and 
MI (OR, 2.09; P=0.007) with BVSs. The relative rates of all-
cause and cardiac death, revascularization, and target lesion 
failure were similar for BVSs and EESs (Zhang X-L et al, Ann 
Intern Med 2016;164:752-763).
Systematic Evidence Review: The Beneficial Effect of 
Aspirin for the Primary Prevention of CVD is Modest 
and Occurs at Doses of ≤100 mg/d / Older Adults Seem 
to Achieve a Greater Relative MI Benefit / Consider 
Bleeding Risk which May Vary Considerably 
According to 2 good-quality and 9 fair-quality randomized, 
controlled trials, aspirin reduced the risk for nonfatal myocar-
dial infarction (MI) (relative risk - RR, 0.78) but not nonfatal 
stroke; aspirin showed little or no benefit for all-cause or 
cardiovascular mortality. Benefits began within the first 5 
years. Older adults achieved greater relative MI reduction, 
but no other effect modifications were found in analyzed 
subpopulations. In trials with aspirin doses of ≤100 mg/d, 
the reduction in nonfatal MI benefit persisted (absolute risk 
reduction, 0.15 to 1.43 events per 1000 person-years) and a 
14% reduction in nonfatal stroke benefit was noted, but no 
benefit was found for all-cause mortality (RR, 0.95) or car-
diovascular mortality (RR, 0.97) (Guirguis-Blake JM et al, 
Ann Intern Med 2016;164:804-813). 
However, in CVD primary prevention studies, low-dose 
aspirin use (≤100 mg daily or every other day) increased 
major gastrointestinal (GI) bleeding risk by 58% (odds ratio 
- OR, 1.58) and hemorrhagic stroke risk by 27% (OR, 1.27). 
Estimated excess major bleeding events were 1.39 for GI 
bleeding and 0.32 for hemorrhagic stroke per 1000 person-
years of aspirin exposure using baseline bleeding rates from 
a community-based observational sample. Such events could 
be greater among older persons, men, and those with CVD 
risk factors that also increase bleeding risk (Whitlock EP et 
al, Ann Intern Med 2016;164:826-835).
Prolonged PR interval is Associated with Significant 
Increases in Atrial Fibrillation, Heart Failure and 
Mortality
The results of a review and meta-analysis of 14 studies 
comprising 400,750 participants suggest an increased risk of 
mortality with prolonged PR interval risk ratio (RR) 1.24 (5 
studies). Prolonged PR interval was associated with significant 
risk of heart failure or left ventricular dysfunction (RR 1.39, 
3 studies) and atrial fibrillation (RR 1.45, 8 studies) but not 
cardiovascular mortality, coronary heart disease or myocardial 
infarction or stroke or TIA. Similar observations were recorded 
when limited to studies of first-degree heart block (Kwok CS 
et al, Heart 2016;102:672-680).
Atrial Fibrillation (AF) in the Setting of Myocardial 
Infarction (MI) (STEMI or NSTEMI) is Associated 
With Impaired 3-Month Outcome
Among 155,071 hospital survivors of MI, AF was docu-
mented in 24,023 (15.5%) cases. The AF subtypes were new-
onset AF with sinus rhythm at discharge (3.7%), new-onset 
AF with AF at discharge (3.9%), paroxysmal AF (4.9%) and 
chronic AF (3%). The event rate per 100 person-years for the 
composite cardiovascular outcome (all-cause mortality, MI 
or ischemic stroke) was 90.9 in patients with any type of AF 
vs 45.2 in patients with sinus rhythm, adjusted hazard ratio 
(HR) 1.28. The composite cardiovascular outcome was simi-
lar among AF subtypes and between NSTEMI and STEMI. 
AF was associated with higher risk of mortality (HR 1.59), 
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reinfarction (HR 1.14) and ischemic stroke (HR 2.29) (Batra 
G et al, Heart 2016;102:926-933). 
XANTUS Study: Patients with Non-Valvular Atrial 
Fibrillation (AF) Receiving Rivaroxaban, Had 2.1 
Major Bleeding Events per 100 Patient-Years, 1.9 
Deaths per 100 Patient-Years, and 0.7 Stroke Events per 
100 Patient-Years
Among 6784 patients treated with rivaroxaban (mean 
patient age 71.5 years, range 19-99; 41% female, and 9.4% 
with documented severe or moderate renal impairment, i.e. 
creatinine clearance <50 mL/min), the mean CHADS2 was 
2.0 and CHA2DS2-VASc score 3.4; 859 (12.7%) patients had a 
CHA2DS2-VASc score of 0 or 1. The mean treatment duration 
was 329 days. Treatment-emergent major bleeding occurred 
in 128 patients (2.1 events per 100 patient-years), 118 (1.9 
events per 100 patient-years) died, and 43 (0.7 events per 100 
patient-years) suffered a stroke (Camm AJ et al, Eur Heart J 
2016; 37:1145-1153).
EMPA-REG OUTCOME® Trial: In Patients With 
Type 2 Diabetes and High Cardiovascular (CV) Risk, 
Empagliflozin Reduced Heart Failure Hospitalization 
and Cardiovascular Death 
The initial EMPA-REG OUTCOME® trial reported that 
empagliflozin added to standard of care reduced major adverse 
CV events in patients with diabetes and high CV risk. In this 
analysis heart failure outcomes were investigated among 7020 
patients randomized to receive empagliflozin 10 mg, empa-
gliflozin 25 mg, or placebo; 706 (10.1%) had heart failure at 
baseline. Heart failure hospitalization or CV death occurred 
in a lower percentage of patients treated with empagliflozin 
(5.7%) than with placebo (8.5%) (hazard ratio, HR: 0.66; P 
<0.001); number needed to treat to prevent one heart failure 
hospitalization or CV death: 35 over 3 years. Empagliflozin 
improved other heart failure outcomes, including hospitaliza-
tion for or death from heart failure (2.8 vs 4.5%; HR: 0.61; 
P <0.001) and was associated with a reduction in all-cause 
hospitalization (36.8 vs 39.6%; HR: 0.89; P=0.003) (Fitchett 
D et al, Eur Heart J 2016;37:1526-1534). 
Danish Databases: All NOACs Safe and Effective 
Alternatives to Warfarin with no Significant Difference 
Between NOACs and Warfarin for Ischemic Stroke / 
Risks of Death or Bleeding Lower for Apixaban and 
Dabigatran vs Warfarin
Among 61678 anticoagulant naïve patients with atrial 
fibrillation (AF) receiving warfarin (n=35436, 57%), dabi-
gatran 150 mg (n=12701, 21%), rivaroxaban 20 mg (n=7192, 
12%), and apixaban 5 mg (n=6349, 10%), NOACs were not 
significantly different from warfarin with regards to ischemic 
stroke. At 1 year, rivaroxaban was associated with lower an-
nual rates of ischemic stroke or systemic embolism (3% vs 
3.3%, respectively) compared with warfarin: hazard ratio – 
HR 0.83. HRs for dabigatran and apixaban (2.8% and 4.9% 
annually, respectively) were non-significant compared with 
warfarin. The annual risk of death was significantly lower with 
apixaban (5.2%) and dabigatran (2.7%) (HR 0.65 and 0.63, 
respectively) compared with warfarin (8.5%), but not with 
rivaroxaban (7.7%). For the combined endpoint of any bleed-
ing, annual rates for apixaban (3.3%) and dabigatran (2.4%) 
were significantly lower than for warfarin (5%) (HR 0.62). 
Warfarin and rivaroxaban had comparable annual bleeding 
rates (5.3%) (Larsen TB et al, BMJ 2016;353:i3189). 
ORBIT-AF Registry: Patients With a Family History 
of AF Developed AF at a Younger Age, had Less 
Comorbidity, and were more Symptomatic. Once AF 
Developed, No Significantly Increased Risks 
Among 9,999 US patients with AF, 1,481 (14.8%) had a 
family history of AF. Relative to those without, those with a 
family history of AF developed AF 5 years earlier (median 
age 65 vs 70 years, P <0.01), with less comorbidity, and had 
more severe AF-related symptoms. No differences were found 
between the 2 groups in the risk of AF progression, stroke, 
non–central nervous system embolism, or TIA, all-cause 
hospitalization, and all-cause death (Gundlund A et al, Am 
Heart J 206;175:28–35). 
CHARGE & FORCe: Consumption of Omega 3s Linked 
to Lower Risk of Fatal Coronary Heart Disease (CHD)
Analysis of 19 cohort studies evaluating biomarkers of 
seafood-derived eicosapentaenoic acid (EPA), docosapen-
taenoic acid (DPA), and docosahexaenoic acid (DHA) and 
plant-derived α-linolenic acid (ALA) for incident CHD, in 
45 637 individuals (median age at baseline 59 years; ~63% 
male) documented 7973 total CHD, 2781 fatal CHD, and 7157 
nonfatal MI events. The ω-3 biomarkers ALA, DPA, and DHA 
were associated with a lower risk of fatal CHD, with relative 
risks (RRs) of 0.91 for ALA, 0.90 for DPA, and 0.90 for DHA. 
Although DPA was associated with a lower risk of total CHD 
(RR, 0.94), ALA (RR, 1.00), EPA (RR, 0.94), and DHA (RR, 
0.95) were not. Significant associations with nonfatal MI 
were not evident. Associations appeared generally stronger in 
phospholipids and total plasma (Del Gobbo LC et al, dx.doi.
org/10.1001/jamainternmed.2016.2925). 
Influenza Infection is Associated with AF (18% Increased 
Risk), which is Reduced with Vaccination
Among 11,374 patients with newly diagnosed AF, those 
with compared with those without influenza infection or vac-
cination (n=38,353), patients with influenza infection without 
vaccination (n=1369) were associated with a significantly 
higher risk of AF with an odds ratio of 1.182 (P=0.032) af-
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ter adjustment for baseline differences. The risk of AF was 
lower in patients receiving influenza vaccination without 
influenza infection (n=16,452) with an odds ratio - OR of 
0.881 (P <0.001). In patients who received vaccination and 
experienced influenza infection (n=696), the risk of AF was 
similar to that in the reference group (OR 1.136; P=NS) (Chang 
T-Y et al, Heart Rhythm 2016; 13:1189–94). 
ARISTOTLE trial: A History of Bleeding is Associated 
With Several Risk Factors for Stroke and Higher Risk 
of Major—but not Intracranial—Bleeding, During 
Anticoagulation / The Beneficial Effects of Apixaban 
over Warfarin for Stroke, Hemorrhagic Stroke, Death, 
or Major Bleeding Remain Consistent Regardless of 
History of Bleeding 
Among 18,140 patients receiving apixaban or warfarin, 
a bleeding history was reported at baseline in 3,033 patients 
(16.7%), who more often were male, with a history of prior 
stroke/TIA/systemic embolism and diabetes; higher CHADS2 
scores, age, and body weight; and lower creatinine clearance 
and mean systolic blood pressure. Major (but not intracranial) 
bleeding occurred more frequently in patients with vs without 
a history of bleeding (hazard ratio 1.35). There were no signifi-
cant interactions between bleeding history and treatment for 
stroke/embolism, hemorrhagic stroke, death, or major bleeding, 
with fewer outcomes with apixaban vs warfarin for all of the 
outcomes independent of a bleeding history (De Katerina R 
et al, Am Heart J 2016; 175:175–183). 
Meta-Analysis: Left Atrial Appendage Occlusion 
(LAAO) is not Superior over NOACs for 
Stroke Prevention, but consistently has Lower 
Thromboembolic & Bleeding events
Per 6 RCTs and 27 observational studies LAAO was less 
effective than NOACs for stroke prevention (odds ratio 0.86), 
but had a lower rate of hemorrhagic events during follow-up. 
However, a meta-proportion analysis of observational studies 
revealed that LAAO was associated with a lower rate of both 
thromboembolic events (1.8 vs 2.4 events per 100 patient-
years) and major bleeding events during follow-up (2.2 vs 2.5 
events per 100 patient-years) as compared with NOACs. With 
prolonged follow-up duration after LAAO implantation, the 
rate of thromboembolic events decreased (Li X et al, Heart 
Rhythm 2016;13:1203–1214). 
Drug-Induced Brugada Syndrome from Noncardiac 
Drugs Occurs Predominantly in Adult Males, Usually 
Late after the Onset of Therapy 
A total of 74 cases of drug-induced Brugada syndrome 
from 27 noncardiac medications were identified: 77% were 
male, and drug toxicity was involved in 46%. It generally oc-
curred weeks after the initiation of therapy. Mortality was 13%. 
All cases had a type I Brugada pattern during drug therapy. 
Nevertheless, their ECG in the absence of drugs was more 
frequently abnormal than the ECG of controls (56% vs 33%, 
P=0.04). Among the cases, 36 (49%) were induced by psycho-
tropic drugs, 20 (27%) were induced by analgesic–anesthetic 
drugs, and 18 (24%) were induced by other noncardiac drugs. 
The most frequently reported agent was intravenous propofol 
(20% of cases). The most frequently reported oral agents were 
lithium (20%) and amitriptyline (16%). The complete list of 
drugs can be found at www.brugadadrugs.org (Konigstein 
M et al, Heart Rhythm 2016; 13:1083–1087). 
Important Review and Other Articles 
2015 ACC/AHA/HRS Guideline for the management 
of supraventricular tachycardia (Page RL et al, J Am Coll 
Cardiol 2016;67:1575-1623), Risk stratification for arrhythmic 
events in patients with asymptomatic pre-excitation (Al-Khatib 
SM et al, J Am Coll Cardiol 2016;67:1624-1638), Drug-
induced QT prolongation and torsade de pointes (Schwartz 
PJ, Woosley RL, J Am Coll Cardiol 2016;67:1639-1650), 
Kawasaki disease (Newburger JW et al, J Am Coll Cardiol 
2016;67:1738-1749), Treatment of venous thromboembolism 
with new anticoagulants (Becattini C & Agnelli G, J Am Coll 
Cardiol 2016;67:1941-1955), Constrictive pericarditis vs 
restrictive cardiomyopathy (Garcia MJ, J Am Coll Cardiol 
2016;67:2061-2076), Asymptomatic severe aortic stenosis 
(Généreux P et al, J Am Coll Cardiol 2016;67:2263-2288), 
Sinus node and atrial arrhythmias (John RM & Kumar S, 
Circulation 2016;133:1892-1900), Dilated cardiomyopathy 
(Japp AG et al, J Am Coll Cardiol. 2016;67:2996-3010), Acute 
ischemic stroke intervention (Khandelwal P et al, J Am Coll 
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